New Zealand’s Commerce Commission has announced a probe into the nation’s pharmaceutical industry. While the Commission had originally ordered changes on the Community Pharmacy Services Agreement last July, the authority is now looking into whether certain clauses in that agreement were created in an attempt to fix prices of prescription medications. According to reports, the agreement prohibited the act of discounting prescription drugs at pharmacies. When the clause was contested by a pharmacy owner, the Commission removed the clauses last December on the basis the agreement was anticompetitive. Now, according to the authority, DHB Shared Services, which added the clauses, as well as the organizations that supported it, are now under investigation.
Featured News
Deutsche Telekom Weighs Mega Merger With T-Mobile US to Form Global Telecom Leader
Apr 22, 2026 by
CPI
Bank Regulators Want to Rewrite the Rules on Money Laundering Enforcement
Apr 22, 2026 by
CPI
RTL Wins Unconditional EU Approval for Sky Deutschland Acquisition
Apr 22, 2026 by
CPI
Anthropic Seeks Court Victory in AI Copyright Dispute Over Song Lyrics
Apr 22, 2026 by
CPI
NFL Defends Streaming Strategy Amid Federal Scrutiny Over Costs and Access
Apr 22, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Competitor Collaborations
Mar 26, 2026 by
CPI
Between Scylla and Charybdis – Navigating Transatlantic Antitrust Currents
Mar 26, 2026 by
Tilman Kuhn & Niklas Brüggemann
Cartel Enforcement Moves Into the Labor Market: Trends and Implications
Mar 26, 2026 by
Andreas Kafetzopoulos & Caroline Janssens
Rethinking Buy-Side Antitrust “Group Boycotts”
Mar 26, 2026 by
Craig Falls & Brendan McGuire
Positive Collaborations: The Tools Available to Competition Authorities to Encourage Beneficial Interactions Between Competitors
Mar 26, 2026 by
Rona Bar-Isaac & Thomas Withers